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ABSTRACT
Urine contains extracellular vesicles (EVs) that concentrate molecules and protect them from
degradation. Thus, isolation and characterisation of urinary EVs could increase the efficiency of
biomarker discovery. We have previously identified proteins and RNAs with differential abun-
dance in urinary EVs from prostate cancer (PCa) patients compared to benign prostate hyperpla-
sia (BPH). Here, we focused on the analysis of the metabolites contained in urinary EVs collected
from patients with PCa and BPH. Targeted metabolomics analysis of EVs was performed by ultra-
high-performance liquid chromatography–mass spectrometry. The correlation between metabo-
lites and clinical parameters was studied, and metabolites with differential abundance in PCa
urinary EVs were detected and mapped into cellular pathways. We detected 248 metabolites
belonging to different chemical families including amino acids and various lipid species. Among
these metabolites, 76 exhibited significant differential abundance between PCa and BPH.
Interestingly, urine EVs recapitulated many of the metabolic alterations reported in PCa, including
phosphathidylcholines, acyl carnitines, citrate and kynurenine. Importantly, we found elevated
levels of the steroid hormone, 3beta-hydroxyandros-5-en-17-one-3-sulphate (dehydroepiandros-
terone sulphate) in PCa urinary EVs, in line with the potential elevation of androgen synthesis in
this type of cancer. This work supports urinary EVs as a non-invasive source to infer metabolic
changes in PCa.
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Introduction
Prostate cancer (PCa) is among the most frequently
diagnosed and deadly types of cancer in men in
Western countries (http://globocan.iarc.fr). Lack of
sensitive and specific diagnostic tools, especially to
detect early stages of the disease, and the unknown
underlying mechanisms of onset and progression of
PCa are the major problems to treat PCa with the
highest efficacy. Thus, there is a high demand to dis-
cover more sensitive and specific biomarkers to
improve PCa diagnosis and prognosis. Nowadays,
prostate-specific antigen (PSA) blood screening tests,
together with clinical T-stage and Gleason score are the
standard tests to discriminate patients with low, inter-
mediate or high risk to suffer PCa [1].
Metabolomics is recognised as the ultimate “omics”
discipline with high potential to identify sensitive and
specific markers, and to understand the mechanisms
involved in the development of pathological processes
[2]. The recent technological revolution in separation
and detection of small molecules, combined with rapid
progress in bioinformatics, is making possible to
rapidly measure a large number of metabolites in a
small amount of sample [3,4]. Metabolomics comprises
the qualitative and quantitative measurement of the
metabolic response to physiological or pathological
stimuli. It involves the extraction and measurement of
low molecular weight molecules (e.g. amino acids,
sugars, bile acids, fatty acids, vitamins, etc.) belonging
to different metabolic pathways to generate metabolic
profiles of cells, tissues or biofluids [5,6]. Previous
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studies have shown the utility of serum metabolite
levels as a diagnostic tool for different cancer types
[7], and in PCa some metabolites have already been
suggested as candidate biomarkers. Increased serum
levels of polyunsaturated fatty acids have been asso-
ciated to reduce risk of PCa, while higher levels of
serum testosterone were associated with an increased
risk of suffering this malignancy [8]. Other metabolo-
mics approaches have reported alterations of acyl car-
nitines, glucose, glycerophospholipids (including
lysophosphatidylcholines and phosphatidylcholines),
amino acids and triglycerides in PCa [9].
Urine samples have been intensely used to identify
PCa biomarkers [10], due to its easy availability and
handling, and its anatomical proximity to the prostate.
As occurs for the serum, there are also several meta-
bolomics studies of urine samples that found altera-
tions in urinary levels of more than 20 metabolites
including N-methyl glycine, kynurenine, uracil, gly-
cerol 3-phosphate, dihydroxybutanoic acid, xylonic
acid, pyrimidine, ribofuranoside and xylopyranose
(reviewed in [11]). These studies have pointed out
that many metabolic pathways may be altered in PCa
including glycine synthesis and degradation, and car-
bohydrate and energy metabolisms. Although all these
metabolites need further clinical validation, they sup-
port the notion that metabolomics constitutes a suita-
ble technology to identify candidate biomarkers
of PCa.
One important drawback of using urine sample for
biomarker discovery is that many of their constituents are
diluted avoiding to be detected by current technologies.
Thus, in order to detect underrepresented molecules, it is
still required to concentrate the sample. In this context,
cell-secreted extracellular vesicles (EVs) are present in all
body fluids, including urine [12], and could provide a
concentrated source of molecules. Thus, a deep analysis
of the urinary EVs composition could open a window of
opportunities to identify more sensitive and specific PCa
biomarkers. In line, a recent lipidomics study performed in
these urinary vesicles from healthy and PCa samples reveal
up to nine lipid species differentially expressed as potential
PCa biomarkers [13] supporting the existence of metabolic
changes in urine EVs from PCa patients.
In the current study, we have compared urinary EVs
obtained from PCa and benign prostate hyperplasia
(BPH) patients, and focused on the analysis of the meta-
bolites that they contain by performing an UHPLC-MS
targeted metabolomics analysis. We evaluated the levels
of 248 metabolites belonging to different chemical nat-
ure including amino acids, nucleosides, vitamins, as well
as different lipid species. Among them, 76 metabolites
were found significantly altered in PCa compared to
BPH. Some of these metabolites were significantly cor-
related with current markers of PCa (e.g. PSA).
Interestingly, dehydroepiandrosterone sulphate was
among the most significantly altered metabolites in
PCa, supporting the notion that beyond their function
as “metabolic machines” [4,14,15], EVs could inform
about metabolic alterations of cancerous tissue.
Materials and methods
Patient samples
All urine samples were obtained from the Basque Biobank
for research (BIOEF, Basurto University hospital) upon
informed consent and with evaluation and approval from
the corresponding ethics committee (CEIC code
OHEUN11-12 and OHEUN14-14). Clinical classification
of the patients is described in Table 1. For each sample,
urine (50 ml) was collected by spontaneous micturition,
centrifuged at 2,000 × g 10min, filtered through a 0.22 μm-
pore membrane and immediately frozen at −80ºC.
Urine extracellular vesicle isolation and
characterisation
To isolate EVs from urine (average ± SEM; 49.7 ± 0.86ml),
the stored samples were thawed, centrifuged at 10,000 × g
for 30 min and the supernatant ultra-centrifuged at
100,000 × g for 75 min. The resulting pellet was washed
with an excess of phosphate-saline buffer (PBS), and again
ultra-centrifuged at 100,000 × g for 60min. Final pellet was
re-suspended in 150 µL of PBS, aliquot generated and kept
at −80°C for further analysis. Protein was determined by
Bradford and obtained 32.7 ± 4.6 (mean±SEM) micro-
grams on average of total purified protein from the initial
Table 1. Clinical classification of the samples.
Disease status Stage Perineural invasion n
Prostate cancer (PCA) (64 ± 4.41) Stage 2 (64 ± 4.12) No (Pn0) (65.5 ± 5.02) 6
Yes (Pn1) (64 ± 3.47) 10
Stage 3 (64.5 ± 4.68) NA 15
Benign hyperplasia (BPH) (70 ± 5.71) NA NA 14
In parentheses are indicated the median ± SD of age for each group of samples.
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urine volume (50 ml). Size distribution of the particles
present in the isolated preparations was determined by
measuring the Brownian motion using a NanoSight
LM10 system equipped with a fast video capture and par-
ticle-tracking software (Malvern, UK). Pre- and post-
acquisition settings were maintained the same for all the
samples and each video was analysed to give the mean,
mode, and median vesicle size, as well as an estimate of the
particle concentration. Then, an average curve was calcu-
lated for each group of patients to be compared among
them.Cryo-electronmicroscopy andWestern-blot analysis
were performed as describe previously [16].
Metabolite extraction and UHPLC-MS analysis
Metabolic profiles of urinary EVs were semi-quantified
using four UHPLC-MS based analytical platforms as
previously described [17,18]. Methanol was first added
to urinary EV preparations, and after brief vortex,
chloroform was added. Both extraction solvents were
spiked with metabolites not detected in unspiked EV
extracts: tryptophan-d5(indole-d5), PC(13:0/0:0), FA
(19:0), dehydrocholic acid, SM(d18:1/6:0), PE(17:0/
17:0), PC(19:0/19:0), TAG(13:0/13:0/13:0), Cer(d18:1/
17:0), ChoE(12:0), anthranilic acid-(ring-13C6), phe-
nylthiohydantoin (PTH)-valine and glycocholic-
2,2,4,4-d4 acid. Samples were incubated at −20°C for
30 min and, after vortex, three different phases were
collected. Platform 1 included fatty acyls, bile acids,
steroids and lysoglycerophospholipids profiling.
Supernatants were collected after centrifugation at
16,000 × g for 15 min, dried, reconstituted in methanol,
resuspended for 20 min and centrifuged (16,000 × g for
5 min) before being transferred to vials for UHPLC-MS
analysis. Platform 2 included glycerolipids, cholesteryl
esters, sphingolipids and glycerophospholipids profil-
ing. Extracts were mixed with water (pH = 9) and after
brief vortex mixing, the samples were incubated for
60 min at −20°C. After centrifugation at 16,000 × g
for 15 min, the organic phase was collected and the
solvent removed. The dried extracts were then recon-
stituted in acetronitrile/isopropanol (50:50), resus-
pended for 10 min, centrifuged (16,000 × g for
5 min) and transferred to vials for UHPLC-MS analy-
sis. Platform 3 included amino acids profiling; 10 μl
aliquots from the extracts prepared for Platform 1 were
transferred to microtubes and derivatised for amino
acid analysis. Finally, Platform 4 consisted in the ana-
lysis of polar metabolites profiling, including central
carbon metabolism. Extracts were mixed with chloro-
form. After brief vortex mixing, water was added and
samples were mixed for 10 min at room temperature.
Afterwards, samples were centrifuged at 16,000 × g for
10 min. The supernatants were collected and dried.
Extracts were then solubilised in water and after cen-
trifugation, supernatants were transferred to vials for
UHPLC-MS analysis.
Chromatographic separation and mass spectrometric
detection conditions employed were previously
described [17,18]. The overall quality of the analysis
procedure was monitored using six repeat injections of
a pooled sample, considered as the quality control sam-
ple. For each of the four analytical platforms, randomised
sample injections were performed, with QC calibration
and validation extracts uniformly interspersed through-
out the entire batch run. Generally, the retention time
stability was <6 s injection-to-injection variation and the
mass accuracy <3 ppm for m/z 400–1200, and <1.2 mDa
for m/z 50–400. Details of lipid nomenclature used in
this work is provided as supplementary material.
Data processing, statistical and bioinformatics
analyses
Amount of urine sample and data normalisation
A similar volume of urine sample (50 ml) from each
patient was employed for obtaining the EV preparations.
Then, the complete EV preparations were analysed by
UPLC-MS metabolomics analysis. The peak intensities
for each metabolite included in the analysis were normal-
ised to the sum of the peak intensities within each sample.
There was no significant correlation (F < Fcrit) between
the sum of the peak intensities used for the normalisation
and the groups being compared in the study.
Missing values imputation
First, metabolites that were not detected in at least 70%
of the whole set of samples were removed from the
analysis. Then, taking the minimal value for each meta-
bolite and dividing it by a factor of 10, missing values
were imputed in order to obtain the final data set.
Univariate analysis
Three different comparisons were established for the
analyses:
● Prostate cancer (PCa) vs benign prostate hyper-
plasia (BPH).
● PCa pathological stage 3 vs PCa pathological stage 2.
● In the PCa pathological stage 2 group, perineural
invasion: Pn1 vs Pn0.
JOURNAL OF EXTRACELLULAR VESICLES 3
The mean and 90%Winsorized-mean for each metabolite
and each group of patients were calculated, as well as,
Student’s t-test or Wilcoxon signed-rank test, depending
on the normality of the data that was assessed using
Shapiro-Wilk test. Median, standard error of the mean
(SEM), the standard deviation (SD), coefficient of variation
and the Interquartile Range (IQR) were also calculated.
Several calculations were performed for the three
distinct comparisons. We calculated the F-test of the
two variances, the Student’s t-test, Wilcoxon signed-
rank and Fold Change for each metabolite. To test the
discriminatory capacity of each metabolite for each one
of the three comparisons we performed Receiver
Operating Characteristic (ROC) analysis, including in
the calculations the values of the Area Under the Curve
(AUC), sensitivity, specificity, positive predictive value,
negative predictive value, Youden index and the opti-
mal cut-off.
For each one of the three pairwise comparisons, we
generated box-plots for those metabolites with signifi-
cant differences between the two groups with adjusted
p-values following Bonferroni methodology. Heatmaps
indicating log2 value of Fold Change and Bonferroni
adjusted p-values were also calculated. Finally, volcano
plots were generated with the log2 Fold Change values
and Bonferroni adjusted p-values.
All statistical analyses were performed using R soft-
ware v3.3.2 (R Development Core Team, 2016; http://
cran.r-project.org) with stats, caret, psych and
OptimalCutpoints package [19]. Boxplots and volcano
plots were generated with ggplot2 R package.
Correlations with clinical parameters such as BMI
were done with cor.test function in R software, using
Spearman’s method. Both rho and p-value for each
metabolite are reported. We studied the correlation of
BMI and metabolite levels with all the samples together
and also dividing samples depending on their clinical
status.
Multivariate analysis
Principal Component Analysis (PCA), Partial Least
Squares-Discriminant Analysis (PLS-DA) and
Orthogonal Partial Least Squares (OPLS) were per-
formed for each pairwise comparison using SIMCA-P
v12.0.1.0 software (Umetrics AB).
Metabolites mapping into cellular metabolic
pathways and identification of primary enzymes
associated with their metabolism
Metabolic pathways were determined with MetScape
v3.1.2 application, running under Cytoscape v3.5.0
software, linking them to KEGG Pathway database
(http://www.genome.jp/kegg/pathway.html). Primary
enzymes involved in the metabolism of the metabolite
of interest, and their corresponding coding genes were
retrieved from KEGG (http://www.genome.jp/kegg/com
pound/) and HMDB (http://www.hmdb.ca/) databases,
using dbWalk utility on bioDBnet database searching
online utility and specifying “9606” (Homo sapiens)
Taxon ID on Organism box (https://biodbnet-abcc.
ncifcrf.gov/db/dbWalk.php), with the following paths:
● For KEGG compounds, we started with enzyme
EC code:
EC Number->UniProt Accession->UniProt Entry
Name->KEGG Gene ID->Gene ID->Gene Symbol-
>Gene ID->GenBank Nucleotide Accession.
● For HMDB compounds, we started with the name
present on HMDB database:
HMDB Metabolite->HMDB Enzyme -> UniProt Entry
Name->Gene Symbol->Gene ID->GenBank Nucleotide
Accession.
For each metabolite included in this step, we
reported:
● For KEGG compounds, the related enzymes EC
number, UniProt Accession, UniProt Entry
Name, KEGG Gene ID, Gene Symbol, GeneID
and the GenBank Nucleotide Accession for the
corresponding transcripts.
● For HMDB compounds, the HMDB enzyme Gene
Symbol, Gene Symbol, Gene ID and GenBank
Nucleotide Accession for the corresponding
transcripts.
Database normalisation: all the datasets used for the
data mining analysis were downloaded from GEO or
TCGA, and subjected to background correction, log2
transformation and quartile normalisation as reported
[20,21]. In the case of using a pre-processed dataset,
this normalisation was reviewed and corrected if
required. For normal vs. PCa comparisons, a two-tailed
t-test is performed in order to indicate if the observed
differences between the groups are significant. For
tumour progression analysis, an ANOVA test was per-
formed in order to evaluate if the observed differences
of gene expression levels between the groups were
significant. DFS analysis was performed using Taylor
and TCGA datasets. In both cases, the patients were
stratified by quartiles based on the expression of the
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gene of interest, Kaplan-Meier Estimator was used in
order to estimate the survival function from different
groups of patients while a Log-Rank test is calculated to
check the significance between the curves. In the case
of Taylor dataset, the analysis was performed using the
average signal from all the transcripts of a gene.
Results
Urine samples were collected from patients with BPH
(n = 14) and PCa (n = 31) with different pathological
characteristics (Table 1). In order to avoid any chemi-
cal alteration of the vesicles that could interfere with
the metabolomics analysis, we decided to preserve uro-
modulin status of the samples by avoiding the use of
high-salt concentration or reducing agents. After initial
clearing at low centrifugation and ultrafiltration, small
EVs (exosomes, small microvesicles and apoptotic
blebs) were isolated by differential ultracentrifugation
as described in [16]. Cryo-electron microscopy
revealed the presence of vesicles in the preparations
(Supplementary Figure 1A). Western-blot analysis
showed that while we could not detect mitochondria
(COX IV) or endoplasmic reticulum (GRP78) proteins,
we could detect exosomal markers (CD10, CD63, CD9,
Flotillin and CD26), and also some uromodulin (THP)
(Supplementary Figure 1B). As previously, we found a
high inter-individual variability in the abundance of
these proteins [16,22]. In agreement with previous
results [16], physical characterisation by NTA analysis
of the isolated material revealed significant differences
in the size distribution of particles isolated from PCa
and BPH samples (Figure 1). Interestingly, the size of
the particles increased with the stage of the PCa, thus,
the major difference was observed between BPH and
PCa stage 3 (Figure 1). A significant higher abundance
of particles bigger than 350 nm were observed in sam-
ples from PCa stage 3 (Figure 1(d)). The mean con-
centration of particles per mL for all samples was
8.60 ± 1.19 × 1010 EVs/mL. No differences were
found for the concentrations of EVs/mL between dif-
ferent groups (BPH, PCa stage 2 Pn0, stage 2 Pn1 and
stage 3).
After this initial characterisation, metabolites pre-
sent in the urinary EV preparations were extracted
using different methodologies in order to cover a
wide range of molecules with different chemical nature
(see Methods section). We were able to detect 248
metabolites (Supplementary Table 1) including amino
acids, vitamins, nucleosides, as well as different lipid
species. Considering all the samples, metabolites with
more than 70% of missing values were eliminated from
the analysis with the exception of PC(14:0/20:4), PC
(0:0/20:3) and TG(56:8) because most of missing values
occur mainly in one of the two groups (PCa or BPH).
Afterwards, we performed three different statistical
analysis comparing BPH and PCa groups, as well as,
the association to tumour stage and perineural
invasion.
Metabolites differentially altered between BPH
and pca
Univariate analysis revealed that 76 out of 248 metabo-
lites showed statistically significant differences between
EVs from PCa and BPH patients. These metabolites
were distributed along most chemical families analysed,
although there was a predominance of phosphatidylco-
lines (PC), fatty acid esters (acyl carnitines) and sterols
(Figures 2, 3 and Supplementary Figure 2). Whereas
higher abundance of PC was observed in BPH samples,
acyl carnitines and sterols were more abundant in PCa
samples (Figures 2 and 3). In addition, carboxylic acids
and glycerolipids were slightly decreased, and vitamins
were increased in PCa EVs. The other families of meta-
bolites including amino acids, bile acids, nucleosides,
sphingolipids, phosphatidylethanolamines (PE) con-
tained both increased and decreased metabolites
(Figure 3). Interestingly, the abundance of ceramides
with short carbon number in their acyl chains were
increased in PCa samples, while ceramides with long
carbon number (>23) in their acyl chains were reduced
in PCa EVs. This pattern was not present in other
sphingolipids families. In the non-esterified fatty acid
family, the abundance of arachidonic acid (20:4n-6)
was decreased in PCa samples, while other polyunsatu-
rated fatty acid with shorter carbon chain (16:3n-x) was
significantly increased in the PCa group (Figure 3).
Multivariate analysis by principal component analy-
sis (PCA) did not show a perfect separation of the two
groups, although PCa EV samples tended to aggregate
all together, whereas BPH samples were more disperse
(Figure 4(a)). Statistics of the model indicate low
degree of fit (2n component R2X = 0.49) and also
low predictability (2n component Q2X = 0.37). The
PCA loadings plot (Figure 4(b)) indicated that the
differences between PCa and BPH samples were
explained mainly by different subfamilies of glycero-
phospholipids, confirming what was identified with the
univariate analysis.
Metabolites differentially altered between PCa
stage 2 and stage 3
PCa stage is a pathological sign of disease aggressive-
ness [1]. In an attempt to identify potential biomarkers
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Figure 1. Size distribution of urinary EVs isolated from the BPH and PCa groups.
Pairwise comparison BPH vs PCa stage 2 without perineural invasion (a), pairwise comparison BPH vs PCa stage 2 with perineural invasion (b) and
pairwise comparison BPH vs PCa stage 3 (c). Size distribution of the particles isolated from each patient, including SEM error bars (d). Number of
samples: BPH (n = 14), Stg.2 Pn0 (n = 6), Stg.2 Pn1 (n = 10) and Stg.3 (n = 13), all of them analysed in duplicate. Kruskal-Wallis Rank Sum test was
applied to study the significance of the sizes distribution differences (*p < 0.05 and **p < 0.01).
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to discriminate between different stages of PCa, we
performed univariate analysis comparing the PCa
stage 2 and stage 3 subgroups. We identified 5 meta-
bolites that showed significant differences between the
two groups (Figure 5(a)). These metabolites were three
ceramides, Cer(d18:1/16:0), Cer(d18:1/20:0), Cer
(d18:1/22:0) one glycerophospholipid PC(30:0) [which
is a combination of the isomers PC(16:0/14:0) and PC
(14:0/16:0)] and one acyl carnitine, stearoylcarnitine
[AC(18:0)]. In addition, we also observed a non-sig-
nificant trend in other metabolite families. Thus, fatty
esters, glycerolipids (both diacylglycerols and triacyl-
glycerols), fatty amides, vitamins and 1-monoethergly-
cerophosphocholines showed an increase in their
abundance in the PCa stage 3 group (Supplementary
Table 1). In contrast, the levels of most of the metabo-
lites belonging to the sphingolipids family including
ceramides, monohexosylceramides and sphingomye-
lins, as well as fatty alcohols, some glycerophospholi-
pids subgroups and nucleosides were reduced in stage
3. In this comparison, unsupervised multivariate ana-
lysis could not achieve any separation between differ-
ent PCa stages, and although supervised PLS-DA
analysis was able to discriminate (R2X 0.47, Q2X
0.07), its loadings plot showed that the major influence
in the separation corresponded to the aforementioned
five metabolites (data not shown) detected in the uni-
variate analysis.
Metabolites differentially altered between PCa
stage 2 perineural invasion: Pn1 vs Pn0
Perineural invasion in PCa has been associated to
prostate cancer prognosis [23]. Although a limited
number of samples were available, we also attempted
to identify metabolites tentatively associated to this
pathological feature. By univariate analysis, we detected
significant lower abundance of cyclic AMP (cAMP)
and higher abundance of the combination of isomers
androsterone sulphate and etiocholanolone sulphate in
the EV samples obtained from PCa patients with peri-
neural invasion (Figure 5(b)). In addition, although not
significant, three bile acids showed lower levels in
samples with perineural invasion (Supplementary
Table 1). Unsupervised multivariate analysis was not
able to separate the two groups of samples, but we
could achieve this separation with PLS-DA test (R2X
0.40, Q2X 0.58) (data not shown).
Correlation analysis of metabolic profiling with
body mass index (BMI)
When studying circulating metabolites, the systemic
metabolic state can be a critical contributing factor
that can influence the results of the analysis.
Obesogenic diets and obesity impact on biofluid meta-
bolite concentration, and can also have a central effect
on tumour tissues [24] by altering their biological
Figure 2. Volcano plot for BPH (n = 14) vs PCa (n = 31).
Positive fold change indicates an increase of the metabolite in PCa, while a negative value indicates that the levels are reduced in PCa. Dots shape
and colour depend on metabolite families.
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features. Therefore, we considered evaluating the
changes in urine EV metabolites that were associated
to the body mass index (BMI). Samples were divided
into three groups, corresponding to their calculated
BMI: lean (<25), overweight (>25 and <30) and obese
(>30). Taking into account all the samples indepen-
dently of their BPH or PCa classification, no significant
correlation was found between BMI and any of the 248
metabolites analysed in this study. Afterwards, we
explored if some metabolites were correlating with
BMI inside different groups. In the lean BMI group,
some sterol-related metabolites including isomer
pregn-5-ene-3,20-diol sulphate and isomer androster-
one sulphate showed significant positive correlations
with rho values of 0.72 and 0.60, respectively
(Table 2). On the contrary, diacylglycerol DG(36:3),
PC(18:2/00) and triglyceride TG(56:3) showed signifi-
cant negative correlation with rho values of −0.71,
−0.69 and −0.67, respectively (Table 2). In the case of
the overweight BMI group, significant positive correla-
tion was found with the exogenous metabolite, hydro-
xyphenyllactic acid (ρ 0.69). Sphingomyelin SM(43:1)
showed significant negative correlation (ρ −0.67) with
BMI values (Table 2). In the obese group, we observed
a high degree of correlation of some metabolites with
the BMI values. Thus, acyl carnitine AC(8:0) (ρ 0.94)
and arginine (ρ 0.85) showed significant positive cor-
relation, while 13 sphingomyelins, 8 phosphatidyletha-
nolamines and the polyunsaturated fatty acid (16:3n-3)
showed negative correlations with rho values ranging
between −0.95 to −0.78) (Table 2). Finally, we evalu-
ated if any of the metabolites correlated with BMI
considering only the PCa group. Inside this group the
highest positive correlations were found for taurocholic
acid and dodecanoylcarnitine, AC(12:0), with rho
values of 0.51 and 0.38, respectively.
Correlation analysis of metabolic profiling with
PSA in the PCa group
PSA is the current gold standard non-invasive prog-
nostic marker for PCa while its diagnostic potential
remains controversial [25]. We performed a correlation
analysis between urinary EV metabolites and the PSA
values determined in our cohort of PCa samples. We
only observed a significant positive correlation (rho
value 0.88) of phosphatidylcoline PC(0:0/20:3), and at
less extent (rho value 0.48) of the primary fatty amide
(20:2n-x).
Analysis of enzymes-associated to metabolites
differentially expressed between PCa and BPH
We have recently shown that metabolic alterations in
PCa are frequently associated to changes in the expres-
sion of key enzymes [21]. To better understand the
cancer cell autonomous nature of the metabolite
changes observed in urine EVs from PCa patients, we
mapped the 76 altered urinary-EV-metabolites into
cellular pathways by using MetScape v3.1.2 [26]. We
identified several pathways that could be affected in
PCa including steroid hormone biosynthesis and meta-
bolism, leukotriene and prostaglandin metabolisms,
linoleate and purine metabolisms, glycerophospholipid
metabolism, TCA and urea cycle, and tryptophan
metabolism. We identified the primary enzymes
involved in the metabolism of each of the 76 differen-
tially expressed metabolites between BPH and PCa, by
using KEGG or HMDB database (see Methods). A
complete list of primary enzymes is supplied as
Supplementary Table 2. Next, we took advantage of
publicly available prostate cancer transcriptomes and
Figure 3. Metabolites associated to urinary EVs differentially
expressed between BPH (n = 14) and PCa samples (n = 31).
Bars have been coloured depending on the significance of the differ-
ences, being lighter gray for the p-values between 0.05 and 0.01,
medium gray for p-values between 0.01 and 0.001 and darker gray
for p-values lower than 0.001.
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we queried the expression of the 149 enzymes in PCa.
We searched for enzymes which expression changes in
PCa would fit the metabolite abundance observed in
urine EVs. From these gene list, we identified 7 genes
with the expression changes (Figure 6) that were con-
cordant with the observed changes in urine EV meta-
bolite abundance among the groups analysed. We
found gamma-aminobutyric acid (GABA) increased
in PCa urine EVs (Figure 3) which was consistent
with a reduction in the expression of Glycine
Amidinotransferase (GATM- use GABA as substrate
for creatine synthesis) (Figure 6(a)). Arachidonic acid
abundance was also altered in urine EV samples, being
reduced in PCa patients compared with BPH
(Figure 3). This fatty acid is the product of phospholi-
pase A2 and it is relevant for the synthesis of pro-
inflammatory metabolites by lipooxygenases.
Interestingly, we found that the expression of two
enzymes (ALOX15 and CYP1A2), that can catabolise
arachidonic acid, was increased in PCa tissue (Figure 6
(b,c). Our metabolomics analysis also showed a con-
sistent decrease in phosphatidylcholine. This could be
explained by decreased synthesis of the phospholipid
or elevated catabolism. When browsing the expression
of PC synthesis and degrading enzymes, we found a
reduction in the expression of Lysophosphatidylcholine
Figure 4. Score (a) and loadings (b) plots of PCA model for the comparison PCa (n = 31) vs BHP (n = 14).
Dots in score plot (A) have been coloured depending on its group (PCa or BHP). Markers in loadings plot (B) have been coloured depending on
metabolite family. AA (amino acids), AC (acyl carnitines), BA (bile acids), Carb (carboxylic acids), CCM (derivative carboxilic acids), Cer (ceramides),
CMH (monohexosylceramides), DAPC (diacylglycerophosphocholines), DAPE (diacylglycerophosphoethanolamines), DAPI (diacylglycerophosphoino-
sitol), DG (diacylglycerols), Exog. (exogenous), FAA (fatty amides), FFA (non-esterified fatty acids), MAPC (1-monoacylglycerophosphocholine), MAPE
(monoacylglycerophosphoethanolamine), MAPI (monoacylglycerophosphoinositol), MEMAPC (1-ether, 2-acylglycerophosphocholine), MEMAPE (1-
ether, 2-acylglycerophosphoethanolamine), MEPC (1-monoetherglycerophosphocholine), MEPE (1-monoetherglycerophosphoethanolamine). See
more details of the nomenclature in supplemental material.
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Acyltransferase 2 (LPCAT2) (Figure 6(d)), which trans-
forms lysoPC into PC, and could provide an explana-
tion for the reduction in PC abundance.
Two urine EV metabolites were associated to increased
perineural invasion in PCa. On the one hand, we found a
decrease in cAMP abundance in EV obtained patients with
perineural invasion. The transcriptional analysis revealed
changes in the expression of enzymes regulating cAMP
synthesis and degradation that were associated to the
aggressiveness of the disease. The expression of adenylate
cyclase 5 (ADCY5) was reduced in PCa (Figure 6(e–g))),
and a further significant reduction was observed from
primary tumours to metastasis. In contrast, the inverse
expression pattern (elevation in PCa and further increase
from primary tumours to metastasis) was detected in the
cAMP degrading enzyme PDE4C (Figure 6(h–j)). In none
of these cAMP metabolising enzymes we could find an
association to altered disease-free survival (Figure 6(g,j)).
On the other hand, the steroid biosynthesis-related
metabolites were among the most elevated in PCa urine
EVs, and associated with increased perineural invasion.
Interestingly, the three metabolites significantly altered
were sulphated steroids in the final steps of androgen
synthesis. Whereas these metabolites are found at detect-
able levels in circulation produced by the adrenal gland, we
evaluated whether enzymes regulating their synthesis or
Figure 5. Differentially-expressed metabolites.
Box-plots of differentially expressed metabolites between PCa stages (A) (stage 2 n = 16 and stage 3 n = 15) and of differentially expressed
metabolites between the presence and absence of perineural invasion (B) (Pn0 n = 6 and Pn1 n = 10). Significance is indicated next to metabolite
name.
10 M. CLOS-GARCIA ET AL.
degradation could be altered in PCa tissue. Strikingly, we
found that the expression steroid sulfatase (STS), which
would remove the sulphate group in androsterone sulphate
andDHEAS, was decreased in PCa, and this reduction was
associated to metastatic disease and reduced disease-free
survival in one out of two datasets (Figure 6(k–m).
Discussion
EVs are produced by normal and cancerous cells and
harbour molecular features of their cells of origin [27].
This encapsulated material can exert biological and meta-
bolic functions [4,14,15,28], which makes them entities of
tremendous interest in cancer biology, both at the level of
Table 2. Correlation analysis of metabolites and BMI.
Metabolite Class Correlation (ρ) p-value
Lean Isomer pregn-5-ene-3,20-diol sulphate Sterol 0.72 0.003
Isomer androsterone sulphate Sterol 0.60 0.011
Taurodeoxycholic acid Bile acid 0.59 0.03
Malate Carboxylic acid (d) 0.56 0.025
Arginine Amino acid 0.53 0.027
Glycine Amino acid −0.56 0.021
TG(18:1 + 20:1 + 18:1) Glycerolipid −0.67 0.006
PC(18:2/0:0) Glycerophospholipid −0.69 0.007
DG(36:3) Glycerolipid −0.71 0.008
Overweight Hydroxyphenyllactic acid Benzyl alcohol (d) 0.69 0.001
L-citruline Amino acid (d) 0.59 0.008
Vitamin B5 Vitamin 0.52 0.024
Proline Amino acid 0.50 0.030
DG(34:1) Glycerolipid 0.49 0.035
4-Pyridoxic acid Pyridine (d) 0.49 0.036
PC(O-16:0/20:4) Glycerophospholipid 0.47 0.042
PE(18:0/18:1) Glycerophospholipid −0.47 0.046
SM(d18:1/17:0) Sphinomyelin −0.48 0.038
Stearoylcarnitine Acyl caritine −0.49 0.037
PE(P-18:0/18:1) Glycerophospholipid −0.50 0.030
PE(16:0/18:2) Glycerophospholipid −0.51 0.027
PE(0:0/20:3) Glycerophospholipid −0.51 0.027
PE(P-16:0/18:2) Glycerophospholipid −0.53 0.021
Alpha-Ketoglutarate Keto-acids (d) −0.54 0.028
PE(18:1/18:2) Glycerophospholipid −0.55 0.017
PE(P-18:0/18:2) Glycerophospholipid −0.56 0.013
AC(12:1n-x) Fatty esters −0.57 0.014
PE(18:2/18:2) Glycerophospholipid −0.57 0.016
SM(43:1) Sphingomyelin −067 0.003
Obese L-Octanoylcarnitine Acyl carnitine 0.94 0.017
Arginine Amino acid 0.86 0.024
PC(O-16:0/18:2) Glycerophospholipid 0.83 0.058
Acylcarnitine(8:1n-x) Acyl carnitine 0.75 0.066
Deoxycholic acid Bile acid 0.75 0.066
PI(18:0/20:4) Glycerophospholipid −0.75 0.066
PE(20:5/16:0) Glycerophospholipid −0.75 0.066
L-Homoserine Amino acid −0.75 0.066
Isoleucine Amino acid −0.75 0.066
SM(43:1) Sphingomyelin −0.79 0.048
SM(d18:1/24:1) + SM(d18:2/24:0) Sphingomyelin −0.79 0.048
SM(d18:1/17:0) Sphingomyelin −0.79 0.048
SM(33:1) Sphingomyelin −0.79 0.048
PE(P-18:0/22:5) + PE(P-20:1/20:4) Glycerophospholipid −0.79 0.048
PUFA (16:3n-x) Fatty acid −0.79 0.048
PE(20:4/18:2) Glycerophospholipid −0.79 0.048
SM(32:1) Sphingomyelin −0.82 0.034
PE(P-16:0/20:4) Glycerophospholipid −0.82 0.034
PE(0:0/22:4) Glycerophospholipid −0.82 0.034
SM(d18:2/22:0) Sphingomyelin −0.86 0.024
SM(d18:1/22:0) Sphingomyelin −0.86 0.024
SM(d18:1/18:0) Sphingomyelin −0.86 0.024
SM(d18:1/16:0) Sphingomyelin −0.86 0.024
PE(18:0/20:4) Glycerophospholipid −0.86 0.024
PE(18:1e/22:4) Glycerophospholipid −0.88 0.008
SM(d18:2/20:0) Sphingomyelin −0.89 0.012
PE(16:0/22:6) Glycerophospholipid −0.89 0.012
SM(42:1) Sphingomyelin −0.93 0.007
SM(d16:1/24:1) Sphingomyelin −0.93 0.007
PE(16:0/20:4) Glycerophospholipid −0.93 0.007
SM(38:1) Sphingomyelin −0.96 0.003
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biomarker discovery and mechanistic. Urine contains EVs
from different parts of the urinary track including kidney
and bladder what has awaked great interest to identify
biomarkers affecting these organs. In addition, the ana-
tomic proximity of urine to the prostate gland and the
already shown presence of tumour cells in the urine sedi-
ment [29,30] support also the development of potential
non-invasive diagnoses of PCa using urine-based markers.
In agreement with our previous results, we find differences
in the size distribution of the urinary EVs between PCa and
BPH [16], which we now report to be associated to disease
stage (Figure 1). Our data show that urine from advanced
PCa patients contains a higher proportion of large EVs
than BPH patients. Given that our EV isolation procedure
(filtration through 0.22 microns, and ultracentrifugation at
10,000 × g) removed most of the large EVs from the
sample, and enrich in small EVs (mostly exosomes and
small microvesicles), this difference could be underesti-
mated in our samples. Importantly, in agreement with
our result, it has already been reported that prostate cancer
cells release large EVs named oncosomes with a size
between 1 and 10 microns [31] that contain a distinct
Figure 6. Gene-enrichment analysis.
In-silico transcriptomics analysis of enzymes directly involved in the metabolism of metabolites differentially expresed between PCa and BPH
samples.
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protein cargo [32]. They have also been detected in circula-
tion in models of PCa and shown that their abundance
correlate with tumoral progression [31]. Although, our
studies have been focused in the smaller EVs, it is interest-
ing that we have also observed this size effect.
In a recent targeted lipidomics analysis of urinary
EVs from healthy and PCa urine samples [13], the
authors analysed 107 lipid species and found that 9 of
them were significantly different between the two
groups. Unlike this study, we have focused ours in
the comparison between PCa and BPH, in an attempt
to provide specific biomarkers to discriminate the two
pathological conditions, and contribute to earlier diag-
nosis, and reduce secondary effects of unnecessary
biopsies, so both studies can be considered comple-
mentary in terms of sample groups. Both studies are
also complementary in the metabolites that they ana-
lyse because different metabolite extraction method
and chromatographic procedures were used.
We report changes in the urine EV metabolome at
both structural and cargo levels. The composition of
the urine EVs analysed in this study varies in the
abundance of phosphatidylcholine species that are
major constituents of membranes. In particular we
found reduced abundance of PCs in the EVs from
PCa samples, in agreement with previously reported
by Puhka and coworkers [33]. This result along with
studies reporting increased abundance of PC in PCa
tissue [34] could suggest that less PC-containing struc-
tures, like membrane vesicles are secreted to the extra-
cellular environment. In addition, to the PC content,
we found additional metabolites from different chemi-
cal nature differentially expressed in EVs from PCa and
BPH samples that could be considered candidate bio-
marker for PCa including as candidate acyl carnitines,
sphingomyelins, and steroids. Although more research
is granted, our results indicate that a bias in EV size
and membrane composition could harbour diagnostic
potential in PCa.
Apart of the potential biomarker value of the iden-
tified metabolites, they are also valuable to indicate
possible metabolic alterations occurring in PCa. We
found reduced levels in PCa urine EVs of arachidonic
acid, the precursor of eicosanoids and prostaglandins
that are important proliferative and inflammatory
modulators. Interestingly, it has been also reported
that arachidonic acid level is lower in prostatic tissue
from PCa patients [35]. In agreement with the reduc-
tion of the substrate arachidonic acid in PCa, it has
been found that the level of their products (12-and 20-
HETE, and PGE2) are higher in the tissue [36,37] and
also in urine [38]. These studies along with many
others have already shown that the metabolism of
arachidonic acid and their products plays an important
role in PCa development, and in fact, represents an
important therapeutics target (reviewed in [39]).
Importantly, our work suggests that the analysis of
this metabolite in EVs isolated from urine samples
may be used to evaluate in a non-invasive manner
what is occurring in prostatic tissue itself in the context
of PCa.
We observed changes in the abundance of metabo-
lites that are carried within the EVs and are a potential
cargo in PCa. It is worth mentioning that intermediary
metabolites of androgen synthesis were among the
most elevated in PCa urine EVs. Moreover, changes
in the abundance of these steroids, together with
cAMP, were significantly associated to perineural inva-
sion. These results uncover the potential of unbiased
urine EV analysis to elucidate novel signalling and
metabolic alterations underlying PCa biology.
Androgen signalling is among the predominant stimuli
supporting PCa growth and the most successful ther-
apeutic approaches have derived from its targeting
[40], since prostate tumours frequently remain andro-
gen dependent even at late-stage [41]. We have
detected 3beta-hydroxyandors-5-en-17-one-3-sulphate
(dehydroepiandrosterone sulphate, DHEAS) in urinary
EVs, and its level was significantly elevated in PCa
samples. This metabolite, along with estrone sulphate,
is one of the main precursor for steroid hormones
including androgens. There are many reports showing
that steroid-related metabolites and enzymes are
important modulators of PCa progression [42]. There
are four different genes coding for enzymes that were
related to this metabolite: STS, SULT1B1, SULT2B1
and SULT2A1. The fact that urine EVs from PCa
patients contain androgen-related metabolites is sug-
gestive of the relevance of this biosynthetic pathway in
the disease and the potential role of EVs in providing
androgen signalling to neighbour or distal cells. Indeed,
expression of STS was reduced in PCa and associated
to disease progression, hence providing a feasible
explanation for the increase in sulfated steroids.
Interestingly, urinary EVs could be used to monitoring
androgen metabolism in a non-invasive manner.
Together with the aforementioned metabolites asso-
ciated to perineural invasion, we also identified mole-
cules that exhibited differential abundance in high
grade tumours. Five metabolites were differentially
abundant between pathological stage 2 and stage 3
PCa, and more than half of them were ceramide spe-
cies. Ceramides are signalling molecules that can reg-
ulate various aspects of cancer cell biology, including
proliferation, survival and cell death [43]. The selective
decrease of ceramides in association with disease
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aggressiveness provides an exciting perspective of how
this family of metabolites could exert cell and non-cell
autonomous functions to limit the progression of PCa.
It is worth noting that sarcosine has been proposed
also as a PCa biomarker [11]. The urine level of this
metabolite was increased in men with metastatic PCa
[44]. However, its utility as a potential diagnostic tool
is unclear, as its validation as a biomarker has failed in
several studies (reviewed in [11,45]). Interestingly, we
have detected sarcosine in urinary EVs, and although
not significant (p = 0.09), its level was decreased in PCa
samples.
Recent molecular and metabolic profiling of PCa
also identifies lipid metabolism as a key pathway that
undergoes metabolic reprogramming [46,47]. These
changes include an upregulation metabolites involved
in de novo lipid biosynthesis [48] and fatty acid β-
oxidation [49]. As consequence, it has been shown
the accumulation in the prostatic tissue of acyl carni-
tines, which are intermediates of fatty acid oxidation
[50]. In agreement with this alteration, we found
increased levels of acyl carnitines in the urinary EVs
from PCa patients. This association of differential
levels of carnitines on PCa EVs with a metabolic shift-
ing towards β-oxidation of fatty acids has already been
proposed by Puhka and coworkers [33].
In summary, in this work we report several meta-
bolites associated to urinary EVs, many of them exhi-
biting differential abundance between BPH and PCa,
and mirroring some of the alterations described
in PCa.
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